Sarepta Therapeutics (NASDAQ:SRPT) Stock Price Down 8% – Time to Sell?

Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) fell 8% on Thursday . The stock traded as low as $21.79 and last traded at $21.86. 2,687,463 shares traded hands during trading, a decline of 8% from the average session volume of 2,915,662 shares. The stock had previously closed at $23.77.

More Sarepta Therapeutics News

Here are the key news stories impacting Sarepta Therapeutics this week:

• Positive Sentiment: Early siRNA Phase 1/2 data (SRP‑1001, SRP‑1003) impressed investors — strong target knockdown, safety and muscle delivery signals sparked the share rally and lifted sentiment on Sarepta. SRPT Stock Surges on Promising Early Results From siRNA Programs
• Positive Sentiment: Options flow has been very bullish — large volume of call purchases suggests traders are positioning for further upside or continued momentum. Investors Buy Large Volume of Call Options on Sarepta Therapeutics (NASDAQ:SRPT)
• Positive Sentiment: At least one major shop (reported coverage) raised its price target after the data, which helped validate the clinical news and contributed to the rally. Sarepta (SRPT) Skyrockets 35% on Morgan Stanley PT Hike, Stellar Trial Results
• Neutral Sentiment: Analyst consensus remains cautious/neutral overall — the stock’s average rating is a “Hold,” reflecting mixed views despite the clinical upside. Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Receives Average Rating of “Hold” from Brokerages
• Neutral Sentiment: Valuation and longer‑term upside are being reassessed: several writeups model potential upside but note the one‑day rebound and remaining execution risks. Assessing Sarepta Therapeutics (SRPT) Valuation After Early siRNA Trial Results
• Negative Sentiment: Some sell/underperform stances persist — Citigroup raised its PT but kept a sell rating, and Needham reaffirmed underperform, highlighting continued skepticism among parts of the sell‑side. These views can cap rallies if the broader data set or guidance don’t follow through. Brokerage Notes (Citigroup/Needham)
• Negative Sentiment: Cautious takeaways from analysts/commentators emphasize the data are early and limited; some warn it’s too soon to extrapolate material commercial potential, which could lead to profit‑taking or volatility. Sarepta Therapeutics: It’s Too Early To Get Excited About siRNA Data

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on the company. Loop Capital set a $25.00 target price on Sarepta Therapeutics in a research report on Tuesday, March 3rd. Royal Bank Of Canada upped their price target on Sarepta Therapeutics from $16.00 to $18.00 and gave the stock a “sector perform” rating in a research report on Thursday, January 8th. Mizuho raised their price target on shares of Sarepta Therapeutics from $26.00 to $31.00 and gave the stock an “outperform” rating in a research note on Thursday, March 12th. Weiss Ratings reiterated a “sell (d)” rating on shares of Sarepta Therapeutics in a report on Monday, December 29th. Finally, Needham & Company LLC reissued an “underperform” rating on shares of Sarepta Therapeutics in a research report on Thursday. Nine investment analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and six have issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $32.30.

Sarepta Therapeutics Trading Down 7.9%

The firm has a market cap of $2.10 billion, a price-to-earnings ratio of -2.37, a P/E/G ratio of 0.34 and a beta of 0.42. The company has a debt-to-equity ratio of 0.73, a current ratio of 2.32 and a quick ratio of 1.48. The business has a 50-day moving average of $18.69 and a 200-day moving average of $19.99.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported ($3.58) EPS for the quarter, missing the consensus estimate of ($0.87) by ($2.71). The company had revenue of $442.93 million for the quarter, compared to analyst estimates of $390.95 million. Sarepta Therapeutics had a negative net margin of 38.34% and a negative return on equity of 50.74%. The business’s revenue for the quarter was down 32.7% on a year-over-year basis. During the same period last year, the company posted $1.90 earnings per share. Research analysts anticipate that Sarepta Therapeutics, Inc. will post 2.67 EPS for the current year.

Insider Activity at Sarepta Therapeutics

In other news, Director Stephen Mayo sold 7,239 shares of the stock in a transaction that occurred on Thursday, March 12th. The stock was sold at an average price of $17.02, for a total value of $123,207.78. Following the completion of the sale, the director owned 1,765 shares of the company’s stock, valued at approximately $30,040.30. This represents a 80.40% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 7.60% of the company’s stock.

Hedge Funds Weigh In On Sarepta Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the company. AQR Capital Management LLC lifted its stake in Sarepta Therapeutics by 454.6% in the fourth quarter. AQR Capital Management LLC now owns 7,796,535 shares of the biotechnology company’s stock valued at $167,781,000 after acquiring an additional 6,390,860 shares during the last quarter. Vanguard Group Inc. increased its stake in shares of Sarepta Therapeutics by 18.1% during the 3rd quarter. Vanguard Group Inc. now owns 10,817,446 shares of the biotechnology company’s stock worth $208,452,000 after purchasing an additional 1,657,267 shares during the last quarter. First Trust Advisors LP increased its stake in shares of Sarepta Therapeutics by 209.1% during the 3rd quarter. First Trust Advisors LP now owns 1,939,781 shares of the biotechnology company’s stock worth $37,380,000 after purchasing an additional 1,312,220 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. raised its holdings in shares of Sarepta Therapeutics by 183.5% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 1,745,051 shares of the biotechnology company’s stock valued at $33,627,000 after purchasing an additional 1,129,610 shares during the period. Finally, Erste Asset Management GmbH raised its holdings in shares of Sarepta Therapeutics by 65.7% in the 3rd quarter. Erste Asset Management GmbH now owns 2,685,945 shares of the biotechnology company’s stock valued at $50,588,000 after purchasing an additional 1,064,530 shares during the period. 86.68% of the stock is currently owned by institutional investors and hedge funds.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.